Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Durata Therapeutics (NASDAQ:DRTX.DL)

CAPS Rating: No stars

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:DRTX.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.00)
Submitted June 23, 2013

Durata has been very weak ahead of the dalbavancin NDA and MAA submissions despite what appears to be solid phase III data and the promise of priority NDA review due to QIDP status. Is the stock weak because no one talks about Durata, since Trius is… More

zzlangerhans (99.00)
Submitted October 08, 2012

It's always difficult to reconstruct the history of a hand-me-down drug but in the case of Durata and dalbavancin, I've seen enough to discourage me from an investment. Dalbavancin is billed as a next-generation vancomycin, with the advantage of a… More

NASDAQ:DRTX.DL VS S&P 500 (SPY)

NASDAQ:DRTX.DL Summary

  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about DRTX.DL.

No one has written a Pitch for DRTX.DL stock yet. Tell us why you think DRTX.DL will outperform or underperform against the market.

Leaderboard

Find the members with the highest scoring picks in DRTX.DL.

No players have picked DRTX.DL yet. Tell us why you think DRTX.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for DRTX.DL.